INTRODUCTION

According to the definition and setting, acute kidney injury (AKI) can occur in 1%-25% of intensive care units (ICUs) admitted patients with a mortality risk of 15%-60% [1]. A systematic review and meta-analysis showed an AKI incidences rate of 21.6% (range, 19.3–24.1) and 33.7% (range, 26.9–41.3) in adults and children, respectively [2]. Different criteria including
Pharmacokinetics changes including alterations in the volume of absorption, distribution, protein binding, cytochromes activity, and elimination in patients with AKI are important factors in treating these patients [5,6]. In addition, hypervolemia, hypoalbuminemia, and augmented renal clearance affect the efficacy and toxicity of antibiotics in patients with AKI [7].

There is no standard formulation for estimating the glomerular filtration rate (GFR) or creatinine clearance (CrCl) [8]. Historically, dosing of medications in AKI people such as patients with GFR <10 ml/min had been recommended; however, this approach was led to underdosing of antimicrobial agents and therefore no longer is recommended [8]. Current guidelines recommend initial higher loading doses (e.g., doses ≥100%–150%) and normal or near-normal maintenance doses [8].

Continuous infusion of inulin, and measurement of inulin clearance with multiple urine samples is the standard method for measuring the GFR; however, it is not practical in ICU settings [9]. Iothalamate, iohexol, CrEDTA (ethylenediaminetetraacetic acid), and cystatin C methods are alternative proposed approaches being used in research studies [9,10]. The urine CrCl is another method widely used in different ICU settings, although it is not standard and has its limitations [11-13]. Different formulas for estimation of GFR or CrCl including Cockcroft-Gault (CG), and chronic kidney disease-epidemiology collaboration (CKD-EPI), and modification of diet in renal disease (MDRD) are used for medication dosing in patients with stable renal function [8]. None of the above-mentioned formulas are precisely estimate GFR in patients with AKI [8]. Other formulations including Chiou and kinetic-GFR, Bratter, and Jelliffe are also recommended for patients with dynamic renal functions [14,15]. However, available guidelines recommend using collected urine (e.g., 1–12 hours) to measure CrCl and beta lactam antimicrobial optimal dosing [8,16]. Therefore, the aim of this study was to compare the correlation between the measured CrCl and static and dynamic formulas in the ICU patients with developed AKI.

KEY MESSAGES
- In patients with acute kidney injury (AKI) dynamic methods like kinetic-glomerular filtration rate (GFR) may be a better prediction for GFR.
- Using Cockcroft-Gault in patients with AKI overestimate GFR.

MATERIAL AND METHODS
The research protocol was approved by the Ethical Committee of Kermanshah University of Medical Sciences (No. IR.KUMS.REC.1399.142. All participants or their family members (in case of unconsciousness, mental disease, or disability) signed the consent form for the study.

Patients
This study was a prospective study conducted on the critically ill patients. The adult patients with AKI were included in this study if they fulfilled the inclusion criteria. Daily serum creatinine and urine outputs before and after the development of AKI were recorded for all the included patients. The AKIN criteria were used for the detection and staging of AKI [17]. As 24 hours urine collection is impractical in critically ill patients, it also may over- or underestimate GFR. Therefore, shorter periods (e.g., 1-, 2-, 4-, 6-, and 8-hour urine collection) have been proposed for quick estimation of CrCl and minimizing procedure error [8,16,18,19]. Six hours urine collection had a good correlation with clearance of medications like vancomycin [18]. Therefore, 6-hour urines were collected and urinary CrCl were measured according to the following formula:

\[ \text{Urinary CrCl (ml/min)} = \text{urine creatinine (mg/dl)} \times \text{urine volume (ml)} / \text{creatinine (mg/dl)} \times \text{time (min)}. \]

The patients with a history of CKD (GFR <60 ml/min), those who received trimethoprim-sulfamethoxazole and cimetidine, patients who had urine outputs <0.5 ml/kg/hr or total positive fluid balance >500 ml, and those needed renal replacement therapy were excluded from this study. In order to eliminate the possible effects of vasopressors, diuretics, and comorbidities like diabetes, hypertension, and underlying heart disease on the correlations of different methods, another analysis was performed in patients without these risk factors [20].

The GFR or CrCl were calculated according to different formulas including CG, modified CG, MDRD, CKD-EPI, Jelliffe, Brater, Chiou, and kinetic-GFR. Dynamic formulas for GFR
Measured creatinine clearance with estimated GFR

Kadivarian S, et al.

The measured creatinine clearance (CrCl) and estimated glomerular filtration rate (GFR) calculation are as followed.

**Brater equation:**

\[
\text{CrCl in male (ml/min per 70 kg)} = \frac{[293 - (2.03 \times \text{age})] \times [1.035 - 0.01685 \times (\text{sCr}_1 + \text{sCr}_2)]}{(\text{sCr}_1 + \text{sCr}_2)} + \frac{49 (\text{sCr}_1 - \text{sCr}_2)}{(\text{sCr}_1 + \text{sCr}_2) \Delta t \text{ day}}
\]

\[\text{CrCl in female = male value} \times 0.86\]

**Chiou equation:**

\[
\text{Creatine volume of distribution} = 0.6 \text{ L/kg}
\]

\[
\text{CrCl in male (ml/min)} = \frac{2 [28 - 0.2 \times \text{age}]}{14.4 (\text{sCr}_1 + \text{sCr}_2)} + 2 \frac{[\text{vd} (\text{sCr}_1 - \text{sCr}_2)]}{(\text{sCr}_1 + \text{sCr}_2) \Delta t \text{ min}} - \text{non renal CrCl} \times \text{IBW}
\]

\[
\text{CrCl in female (ml/min)} = \frac{2 \times \text{IBW} [22.4 - 0.16 \times \text{age}]}{14.4 (\text{sCr}_1 + \text{sCr}_2)} + 2 \frac{[\text{vd} (\text{sCr}_1 - \text{sCr}_2)]}{(\text{sCr}_1 + \text{sCr}_2) \Delta t \text{ min}} - \text{non renal CrCl} \times \text{IBW}
\]

CrCl means creatinine clearance; sCr 1, 2: first and second serum creatinine values; Vd: creatinine volume of distribution (0.6 L/kg); and IBW: ideal body weight.

**Kinetic-GFR:**

\[
\text{Non-renal CrCl} = 0.048 \text{ ml/min} \cdot \text{kg}^{-1}
\]

**Kinetic-GFR:**

\[
\text{Kinetic-GFR} = \left(\frac{\text{steady state serum creatinine (mg/dl)} \times \text{CrCl (ml/min)}}{\text{mean plasma creatinine}}\right) \times \left(1 - \frac{24 \times \text{plasma creatinine}}{\Delta \text{ time (hr)} \times \left(\max\Delta \text{plasma creatinine/day}\right)}\right)
\]

Delta plasma creatinine refers to the change in plasma creatinine. It is defined as the ending creatinine minus the starting creatinine. Δ time (hr) is the interval in hours between two consecutive creatinines. MaxΔ plasma creatinine/day refers to the maximal change (increase) in the plasma creatinine that can occur per day if renal function is completely lost.

Furthermore, dosing of prescribed antibiotics was compared with dosing in the available resources including online Lexicomp, Sanford guide and nomograms, and under- or over-dosing were determined [21]. If a patient had normal serum creatinine and measured CrCl >130 ml/min, he/she would be considered as having augmented renal clearance [22].

The main outcome of the present study was the comparison between the measured 6-hour CrCl and formulas including CG, modified CG, modified CG, MDRD, CKD-EPI, Jelliffe, Brater, Chiou, and kinetic-GFR. The secondary outcome was evaluation of antimicrobial prescription dosing pattern in the patients with AKI.

**Analysis**

The data was analyzed using SPSS ver.16 (SPSS Inc., Chicago, IL, USA). The categorical variables were expressed as numbers and percentages, and the chi-square test and Fisher’s exact test were used for comparing the variables between the two groups. The continuous variables were reported as mean±standard deviation. The Kolmogorov-Smirnov test was used for determining the normally distributed variables. The normally distributed continuous variables were compared by the use of the student t-test, and the non-normally distributed variables were compared using the Mann-Whitney rank-sum test. The correlation between the measured and calculated GFR was obtained by the use of Spearman’s correlation coefficient test. The P-values less than 0.05 were considered to be statistically significant.

**RESULTS**

During the study period, 95 patients with AKI were recorded according to the AKIN criteria (Figure 1). Most of the patients (66.3%) were male. The mean age of the participants was 63.11±17.58 years. The mean serum creatinine at baseline and after AKI were 1.06±0.30 mg/dl and 2.04±0.84, respectively (Table 1). The mean Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE) II scores of all the participants were 8.09±3.52 and 20.09±7.52, respectively (Table 1). The mean measured CrCl in all the participant was 45.28±12.51 ml/min. The most common reasons for admission include the accidents of neurological problems (49.45%) and solid cancers 10.52%. Only 20% of the patients did not have any risk factor for renal failures (Table 2). Table 3 shows the correlations between different formulas and the measured CrCl. None of the formulations had a high or very high correlation with the measured CrCl (Table 3). Most of the patients (77.89%) were in the stage 1 of AKI according to the AKIN criteria, followed by stage 2 (14.73%) and stage 3 (7.36%). In addition, three patients (all were in stage 1 of AKI) did not have any risk factor for renal failures.
on AKI) had criteria for augmented renal clearance. As shown in the Table 4, a significant moderate correlation was observed between the GFR calculated by the Brater formula and the measured CrCl (r=0.40, P<0.001). In the patients being in stage 2 of AKI, only kinetic-GFR had a high correlation with the measured CrCl (r=0.76, P=0.004) (Table 4). Chiou and Jelliffe (r=0.26), kinetic-GFR (r=0.76), and Jelliffe and kinetic-GFR (r=0.37) had the highest correlation coefficients in stages 1, 2, and 3 of AKI, respectively.

When the patients who received loop diuretics (n=24) were excluded from the analysis, a significant moderate correlation was obtained for Jelliffe (r=0.46, P<0.001) and kinetic-GFR (r=0.46, P<0.001) formulations. In addition, when the patients

Table 2. Past medical history

<table>
<thead>
<tr>
<th>Variable</th>
<th>No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No past medical history</td>
<td>19 (20.00)</td>
</tr>
<tr>
<td>HTN</td>
<td>19 (20.00)</td>
</tr>
<tr>
<td>Solid tumor</td>
<td>12 (12.63)</td>
</tr>
<tr>
<td>HTN+DM</td>
<td>8 (8.42)</td>
</tr>
<tr>
<td>Other</td>
<td>37 (38.94)</td>
</tr>
<tr>
<td>HTN: hypertension; DM: diabetes mellitus.</td>
<td></td>
</tr>
</tbody>
</table>

Table 3. Correlation of different formula with measured creatinine clearance

<table>
<thead>
<tr>
<th>Formula</th>
<th>Mean GFR</th>
<th>Correlation coefficient</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modified CG</td>
<td>38.97±17.16</td>
<td>0.30</td>
<td>0.006</td>
</tr>
<tr>
<td>MDRD</td>
<td>40.37±17.53</td>
<td>0.24</td>
<td>0.031</td>
</tr>
<tr>
<td>CKD-EPI</td>
<td>37.49±17.61</td>
<td>0.27</td>
<td>0.015</td>
</tr>
<tr>
<td>Kinetic-GFR</td>
<td>33.85±17.45</td>
<td>0.29</td>
<td>0.008</td>
</tr>
<tr>
<td>Brater</td>
<td>58.94±25.33</td>
<td>0.41</td>
<td>0.010</td>
</tr>
<tr>
<td>Chiou</td>
<td>40.19±20.67</td>
<td>0.26</td>
<td>0.018</td>
</tr>
<tr>
<td>CG</td>
<td>41.51±17.31</td>
<td>0.26</td>
<td>0.018</td>
</tr>
<tr>
<td>Jelliffe</td>
<td>36.43±18.97</td>
<td>0.32</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Values are presented as mean±standard deviation. 
GFR: glomerular filtration rate; CG: Cockcroft-Gault; MDRD: modification of diet in renal disease; CKD-EPI: chronic kidney disease-epidemiology collaboration.

Table 4. Correlation coefficients of formulas in each stage of AKI

<table>
<thead>
<tr>
<th>Formula</th>
<th>Stage 1</th>
<th>Stage 2</th>
<th>Stage 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modified CG</td>
<td>0.24</td>
<td>0.53</td>
<td>-0.03</td>
</tr>
<tr>
<td>MDRD</td>
<td>0.17</td>
<td>0.07</td>
<td>0.03</td>
</tr>
<tr>
<td>CKD-EPI</td>
<td>0.20</td>
<td>0.29</td>
<td>0.00</td>
</tr>
<tr>
<td>Kinetic-GFR</td>
<td>0.17</td>
<td>0.76</td>
<td>0.37</td>
</tr>
<tr>
<td>Brater</td>
<td>0.23</td>
<td>0.51</td>
<td>0.18</td>
</tr>
<tr>
<td>Chiou</td>
<td>0.26</td>
<td>0.26</td>
<td>0.03</td>
</tr>
<tr>
<td>CG</td>
<td>0.19</td>
<td>0.23</td>
<td>0.10</td>
</tr>
<tr>
<td>Jelliffe</td>
<td>0.25</td>
<td>0.51</td>
<td>0.37</td>
</tr>
</tbody>
</table>

AKI: acute kidney injury; CG: Cockcroft-Gault; MDRD: modification of diet in renal disease; CKD-EPI: chronic kidney disease-epidemiology collaboration; GFR: glomerular filtration rate.

Values are presented as mean±standard deviation or number (%).
SOFA: Sequential Organ Failure Assessment; APACHE: Acute Physiology and Chronic Health Evaluation; AKI: Acute Kidney Injury.
who received vasoactive agents (n=12) were excluded from the analysis, a significant moderate correlation was observed for Jelliffe (r=0.45, P<0.001) and kinetic-GFR (r=0.45, P<0.001). Once the patients who received both diuretics and vasoactive agents were excluded (n=39), a high correlation was found for kinetic-GFR (r=0.60, P<0.001). Furthermore, all the formulations had significant correlation coefficients of more than 0.7 when only the patients with no risk factors for acute decline in CrCl.

Vancomycin, meropenem, and piperacillin-tazobactam were the most commonly prescribed antibiotics (Table 5). As shown in Table 5, over- and under-dosing of antibiotics were common in our study. Vancomycin underdosing 19.23% (10/52) or overdosing 32.69% (17/52) and meropenem overdosing 39.53% (17/43) were commonly observed as well. Vasoepressors and Loop diuretics were prescribed for 18.94% (18/95) and 7.36% (7/95) of the patients, respectively. Low doses (200–300 mg/ day) of hydrocortisone for septic shock were prescribed for 13.75% of the patients. In addition, venous thromboembolism prophylaxis without adjustment with enoxaparin was prescribed for 27.3% of the patients. Metoclopramide as prokinetic was needed for 25% of the patients.

**DISCUSSION**

The results of this study showed that none of the available formulas had a high or very high correlation with the measured CrCl in all the stages of AKI. In the critically ill patients with stable renal function CG and ideal body weight, a high correlation with inulin clearance (r=0.75, P<0.001) was found in a study by Roberts et al [23]. However, in the patients with AKI and unstable serum creatinine, measuring GFR was challenging. Evaluating the correlations between urine CrCl and CG, MDRD, and Jelliffe, Bouchard et al. [24] found significant correlations: CG (r=0.67), MDRD (r=0.89), Jelliffe (r=0.75), and modified Jelliffe (r=0.72). Furthermore, the modified CG overestimated and the modified Jelliffe underestimated GFR compared with the measured urine clearance [24].

In the present study, none of the tested formulas had a high or very high correlation with the measured urine CrCl. Jelliffe and kinetic-GFR designed for patients with unstable renal (fluctuation in serum creatinine) functions [14,25]. Recently, Pelletier et al. [26] have used the measured GFR according to radioisotopic 99mTc-DTPA (diethylenetriaminepenta-acetic acid) as a standard tool and compared it with Jelliffe, kinetic-GFR, and the measured urinary CrCl in 119 patients with AKI. They showed that there was good correlations between Jelliffe and kinetic-GFR equations and measured GFR (0.73 and 0.68, respectively). However, the adjusted analysis showed correlations of 0.63 and 0.47 for Jelliffe and kinetic-GFR, respectively, with reference GFR [26].

In our study, almost the same correlations were obtained for Jelliffe and kinetic-GFR. However, the correlations were lower than those observed by Al-Dorzi et al. [11]. They evaluated the correlations between different formulas and a measured 24-hour CrCl in critically ill patients with different renal functions. Although the results showed a high correlation between the measured CrCl and the formulas, a significant bias was observed in the sensitivity analysis. Therefore, they concluded that none of the commonly used formulas are able to estimate a 24-hour CrCl [11].

Carlier et al. [27] showed that the measured 1–2 hours CIrC had a better correlation with 24-hour urinary inulin clearance compared with the collected 24-hour urine CIrC. Using iothalame and inulin clearances is not practical for all the AKI episodes. Unfortunately, urine CrCl may overestimate GFR by 10%–20% in normal renal function, which can increase as renal function decreases [28]. In a subset of the patients who did not have any risk factors for renal failure, all the formulations used had a good correlation with all the formula such as kinetic-GFR and Jelliffe. It should be noted that most of the patients were in stage 1 of AKI and the guidelines recommended to consider changes in drug dosing in stage 2 of AKI [29].

All formulations, including the dynamic formulas, assume a constant rate of creatinine production and volume of distribution and may underestimate AKI severity [30]. Fluid overload may lower serum creatinine concentration and underestimate CrCl [31]. Corrected Jelliffe method has been recommended for the patients with aggressive fluid administration to eliminate the effects of positive fluid balance on se-

---

**Table 5.** Dosing of the frequently prescribed antibiotics in the patients with acute kidney injury

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Frequency</th>
<th>Underdosed</th>
<th>Optimum</th>
<th>Overdosed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vancomycin</td>
<td>52</td>
<td>10</td>
<td>25</td>
<td>17</td>
</tr>
<tr>
<td>Meropenem</td>
<td>43</td>
<td>1</td>
<td>25</td>
<td>17</td>
</tr>
<tr>
<td>Piperacillin-tazobactam</td>
<td>25</td>
<td>4</td>
<td>17</td>
<td>4</td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>24</td>
<td>1</td>
<td>15</td>
<td>8</td>
</tr>
<tr>
<td>Imipenem/cilastatin</td>
<td>8</td>
<td>1</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Ampicillin/sulbactam</td>
<td>6</td>
<td>1</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Colistin</td>
<td>5</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>
rum creatinine concentration [32]. However, the patients with positive total fluid balance >500 ml were not included in the present study. Similar to our results, a recent study by Sangla et al. [33] on critically ill patients showed that the kinetic-GFR estimation model show a better performance than CG and MDRD do in the patients with unstable renal dysfunctions. In addition, they observed that all the methods including CG, MDRD, CKD-EPI, kinetic-GFR, the measured GFR overestimated GFR [33]. A bias of 21 ml/min/1.73 and an accuracy of 35% were observed for urinary GFR method [33]. Considering these limitations for statistical formulas on the kidney disease, improving the Global Outcomes guidelines about dosing in acute and CKD are recommend for dosing in patients with AKI using the measured ClCr [8]. In addition, the measured CrCl is recommended for detecting the augmented renal clearance [34].

In the present study, a higher correlation was found for kinetic-GFR in the patients with the stage of 2 of AKI. In addition, after exclusion of patients who received diuretics and vasopressors a correlation of 0.6 was found. Previous studies showed a different effect of diuretics and vasopressors on GFR [35]. Although diuretics increase urine output and renal perfusion but they didn’t associate with an increased GFR [36]. Norepinephrine and terlipressin administration were associated with increase urine output and GFR in patients with septic shock [36]. However, other factors including the rate of creatinine generation, filtration, fluid administration, and time from AKI occurrence may influence the correlations [37]. After exclusion of patients with mentioned risk factors, our results showed all formulas had a high correlation between measured CrCl and calculated values. Similar results were obtained from a study by Bouchard et al. [24]. They showed that Jelliffe and modified Jelliffe are more precise than other formulas, baseline serum creatinine in our study was lower (2.04±0.82 vs. 3.8±1.6) [24]. However, Hoste et al. [38] found CG and MDRD were not correlated with 1-hour measured CrCl.

Over- or under-dosing of antibiotics including vancomycin, piperacillin-tazobactam, and meropenem were common in the present study. Some experts recommended postponing antibiotics dose reduction in the early stages of AKI (i.e., 24–48 hours) for antibiotics with wide safety margins like beta-lactams due to low toxicity [30]. However, postponing dose adjustment for vancomycin and other nephrotoxic agents is not recommended [30]. One reason for overdosing of meropenem was the presence of multi-drug resistant organism in our ICU. The current guidelines for dosing of beta-lactams in multidrug resistant organisms recommend Cmax/MIC of 4–8 for multi-drug resistant Gram-negative organisms [16]. However, in the present study, dosing of the prescribed antibiotics was compared with nomograms which can influence our conclusions [18]. Recently, Kwong et al. [39] showed that kinetic-GFR can be a better formula for antibiotics dosing and prevention of their toxicity or underdosing [40]. Furthermore, kinetic-GFR can be a better formula for prediction of AKI and mortality [40,41]. In our study, three patients fulfilled the criteria for the augmented renal clearance, as this phenomenon was occurring in up to 30% of the critically ill patients [34]. Therefore, measuring of urinary CrCl is a helpful way to prevent under-dosing of antibiotics in this population.

In our study, patients GFR ≥60 ml/min were prospectively evaluated for the occurrence of acute kidney injuries. In the present study, patients GFR ≥60 ml/min were prospectively evaluated for the occurrence of acute kidney injuries. Correlation between the measured CrCl and estimated GFR in patients without risk factors for developing AKI, and those who had not received vasopressors and diuretics, were analyzed separately and dosing of antibiotics were compared with standard mammograms. However, there some limitations, which can influence our conclusions. First, we were not able to measure GFR with standard methods including inulin, iohexol or iothalamate clearance. Second, antimicrobial therapeutic monitoring for beta-lactams was not available in our center and we were not able to compare dosing according to different formulas.

The results of the present study showed that none of the available formula had a high or very high correlation with the 6-hour measured CrCl. However, kinetic-GFR and Jelliffe, although not perfect, are better formulas for estimating CrCl in patients with AKI. Further studies are needed to use the standard methods in order to clarify the role of different static and dynamic formulas for medication dose adjustment.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

ORCID

Sara Kadivarian https://orcid.org/0000-0002-0233-4261
Fatemeh Heydarpour https://orcid.org/0000-0002-2441-7332
Hasanali Karimpour https://orcid.org/0000-0003-2126-0955
REFERENCES